Mucoepidermoid carcinoma medical therapy
|
Mucoepidermoid carcinoma Microchapters |
|
Differentiating Mucoepidermoid Carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Mucoepidermoid carcinoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Mucoepidermoid carcinoma medical therapy |
|
Risk calculators and risk factors for Mucoepidermoid carcinoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Badria Munir M.B.B.S.[2] , Maria Fernanda Villarreal, M.D. [3]
Overview
There is no medical treatment for mucoepidermoid carcinoma. Radiotherapy can be neoadjuvant treatment in some lesions (dependent on the tumor stage and size).[1]
Medical Therapy
There is no medical treatment for mucoepidermoid carcinoma. Radiotherapy can be neoadjuvant treatment in some lesions (dependent on the tumor stage and size).[1] In general, salivary gland neoplasms respond poorly to chemotherapy, and adjuvant chemotherapy is currently indicated only for palliation. Doxorubicin- and platinum-based agents are most commonly used with the platinum-based agents that induce apoptosis versus the doxorubicin-based drugs that promote cell arrest. Platinum-based agents, in combination with mitoxantrone or vinorelbine, are also effective in controlling recurrent salivary gland malignancy. A new form of 5-fluorouracil called fluoropyrimidine that has increased activity against malignant cells and while having fewer gastrointestinal side effects has shown to be efficacious against malignant salivary cancers and to potentiate the effects of radiotherapy by increasing apoptosis.
Newer trials with antimicrotubule agents with and without concomitant radiotherapy have shown efficacy. Using a platinum-based agent, cisplatin, and an antimicrotubule drug, docetaxel, with radiation shows some promise in advanced carcinomas of the salivary gland. Using paclitaxel (Taxol), another antimicrotubule drug, alone has had moderate activity against mucoepidermoid tumors and adenocarcinomas but no effect adenoid cystic carcinoma.[2]
Various targeted biologic agents such as trastuzumab, imatinib, and cetuximab are currently being investigated.
References
- ↑ 1.0 1.1 Evans HL (1984). "Mucoepidermoid carcinoma of salivary glands: a study of 69 cases with special attention to histologic grading". Am. J. Clin. Pathol. 81 (6): 696–701. PMID 6731349.
- ↑ Stenner M, Klussmann JP (March 2009). "Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved". Eur Arch Otorhinolaryngol. 266 (3): 333–41. doi:10.1007/s00405-008-0882-7. PMID 19052760.